Effects of (1,3), (1,6)-Beta-D-glucan on Insulin Sensitivity and Inflammatory Markers of the Metabolic Syndrome
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 11
- Locations
- 1
- Primary Endpoint
- Beta-D-glucan induced changes in inflammatory markers, adipokines, and gut hormones. Changes in insulin-sensitivity.
Study Overview
Brief Summary
Insoluble (1,3),(1,6)-beta-D-glucan from bakers yeast are indigestible polysaccharides. Previous studies indicate that the intake of insoluble dietary fiber is strongly associated with reduced risk of type 2 diabetes and cardiovascular disease. However, the mechanisms leading to this phenomenon are largely unknown.
There are close relations between metabolic and inflammatory pathways, and a number of hormones, cytokines, signal proteins, bioactive lipids, and transcription factors have been shown to be involved in both systems.
Beta-D-glucans have been suggested to play a role as so called biological response modifiers. Studies in animals indicate that even small doses of (1,3),(1,6)-beta-D-glucan may have beneficial effects on immune activity, i.e., by reducing the secretion of inflammatory factors.
The investigators hypothesize that the intake of isolated (1,3), (1,6)-beta-D-glucan from bakers yeast improves inflammatory makers and insulin-sensitivity in overweight subjects with increased C-reactive protein concentrations at baseline.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy subjects with normal glucose tolerance (NGT)
- •Impaired glucose tolerance (IGT)
- •Impaired fasting glucose (IFG)
Exclusion Criteria
- •Any severe cardiac disease
- •Kidney diseases
- •Type 1 or type 2 diabetes
- •Chronical and acute inflammatory diseases
- •Lipid lowering drugs
- •Cortisone
- •Antibiotics
- •Non-steroidal antiinflammatory drugs
- •Including low dose acetylsalicylic acid
Arms & Interventions
x
capsules containing beta glycan
Intervention: Beta-D-Glucan (Dietary Supplement)
y
capsules containing placebo (waxy maize starch)
Intervention: placebo (Dietary Supplement)
Outcomes
Primary Outcomes
Beta-D-glucan induced changes in inflammatory markers, adipokines, and gut hormones. Changes in insulin-sensitivity.
Time Frame: 3 days
Secondary Outcomes
- Altered gene expression in adipose tissue if changes in primary outcome measures are shown.(3 days)
Investigators
Weickert, Martin O.
Chief Investigator
German Institute of Human Nutrition